Pliant Therapeutics (PLRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Fibrosissrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 50/100 (MEDIUM), 14.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.13% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
- Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
- Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
- Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
- Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
- Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study. — Nat Commun 2026 Jul 31 PMID 42538332
- Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. — Cancer 2026 Aug 1 PMID 42487497
- Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer. — JAMA Netw Open 2026 Jul 1 PMID 42461627
- Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry. — RMD Open 2026 Jun 23 PMID 42336611
- Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON. — Pediatr Pulmonol 2026 Jun PMID 42324891
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Pliant Therapeutics.
Full PLRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.